The 8 most recent market catalysts affecting $VTRS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 65
Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25
Oppenheimer analyst Les Sulewski has initiated coverage on Viatris (VTRS) with an 'Outperform' rating and a $25 price target. This event is significant because new analyst coverage…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 65
Viatris Secures Japan Approval For WAKIX In Treating Excessive Daytime Sleepiness Linked To Sleep Apnea And Narcolepsy
Viatris has received regulatory approval in Japan for WAKIX (pitolisant) to treat excessive daytime sleepiness linked to sleep apnea and narcolepsy. This is a positive development …
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 65
Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20
Leerink Partners' analyst Daniel Clark has initiated coverage on Viatris (VTRS) with an 'Outperform' rating and a $20 price target. This event is significant as new analyst coverag…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 55
Argus Research Maintains Buy on Viatris, Raises Price Target to $20
Argus Research analyst Jasper Hellweg maintained a 'Buy' rating on Viatris and raised the price target from $15 to $20. This action signals increased confidence from a reputable re…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 75
Viatris shares are trading lower despite reporting better-than-expected Q2 financial results, possibly dragged down by wider GAAP net loss, near-term supply risks, and weakness in Emerging Markets.
This headline highlights a significant corporate catalyst for Viatris. While revenue beat expectations, the market is reacting negatively to underlying issues like a wider GAAP net…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Viatris (VTRS) is undergoing a strategic divestiture of its Tyrvaya asset to Harrow Inc. (HROW) for up to $100 million, allowing Viatris to concentrate on core growth areas like co…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 92
Viatris Q2 Adj. EPS $0.69 Beats $0.60 Estimate, Sales $3.756B Beat $3.675B Estimate
Viatris announced Q2 adjusted EPS of $0.69, significantly beating the $0.60 estimate, and sales of $3.756 billion, surpassing the $3.675 billion estimate. This strong financial per…
Jul 14, 2026
Corporate Catalyst
Neutral
Impact 55
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
This filing provides a curated list of analyst ratings and recent news for three high-dividend healthcare stocks: Viatris, Medtronic, and GSK. For Viatris, two analysts maintained …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.